Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
615 stopped studies mapped to Melanoma and descendants · 90% state a reason
Over the 615 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04789668 | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases | Phase 1 / Phase 2 | terminated | Mar 9, 2021 | M.D. Anderson Cancer Center | Insufficient accrual | Enrollment / accrual |
| NCT06799533 | A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and… | Phase 1 | terminated | Jan 29, 2025 | Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety and/or… | Safety / toxicity |
| NCT00421317 | Imatinib in Adult Patients With Metastatic Ocular Melanoma(O-Mel-Inib) | Phase 2 | terminated | Jan 11, 2007 | Centre Oscar Lambret | Study stopped at the end of the first step | Other (stated, no rule matched) |
| NCT02439008 | Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word… | N/A | terminated | May 8, 2015 | Centre Oscar Lambret | Lack of patient enrollment | Enrollment / accrual |
| NCT05926960 | A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study…(PORTSIDE) | Phase 2 | terminated | Jul 3, 2023 | Pfizer | Study terminated due to inability to recruit the target number of patients. There were no safety… | Safety / toxicity |
| NCT06287463 | Study of DCC-3084 in Participants With Advanced Malignancies Driven by the… | Phase 1 | terminated | Mar 1, 2024 | Deciphera Pharmaceuticals, LLC | Trial terminated due to a business decision, not based on any safety concerns. | Safety / toxicity |
| NCT03716193 | Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron… | N/A | terminated | Oct 23, 2018 | West Virginia University | Terminated March 22, 2022 due to COVID-19 pandemic | COVID-19 / pandemic |
| NCT04093323 | Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and… | Phase 2 | terminated | Sep 18, 2019 | Roswell Park Cancer Institute | Funding completed | Funding |
| NCT03428581 | Preventing Lymphedema in Axillary Lymph Node Dissection | N/A | terminated | Feb 9, 2018 | Mayo Clinic | slow accrual; diminished funding | Enrollment / accrual |
| NCT06587451 | Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to… | Phase 3 | terminated | Sep 19, 2024 | Sandoz | In light of the evolving regulatory landscape and growing indications that major Health Authorities… | Sponsor / business decision |
| NCT05551117 | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant…(Tamarack) | Phase 2 | terminated | Sep 22, 2022 | MacroGenics | Business reasons | Sponsor / business decision |
| NCT04913220 | A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With… | Phase 1 / Phase 2 | terminated | Jun 4, 2021 | Sanofi | Early discontinuation based on strategic sponsor decision not driven by any safety concerns | Safety / toxicity |
| NCT03957551 | Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma | Phase 1 / Phase 2 | terminated | May 21, 2019 | John Rieth | Study was terminated early due to changes in the treatment of melanoma | Other (stated, no rule matched) |
| NCT04157517 | A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in… | Phase 1 / Phase 2 | terminated | Nov 8, 2019 | Teva Branded Pharmaceutical Products R&D LLC | Study was terminated early due to futility. | Efficacy / futility |
| NCT03865212 | Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma | Phase 1 | terminated | Mar 6, 2019 | Mayo Clinic | Lack of funding; lack of objective response | Funding |
| NCT05002569 | A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab…(RELATIVITY-098) | Phase 3 | terminated | Aug 12, 2021 | Bristol-Myers Squibb | Inability to meet protocol objectives | Other (stated, no rule matched) |
| NCT03746431 | A Phase 1 Study of [225Ac]-FPI-1434 Injection | Phase 1 | terminated | Nov 19, 2018 | Fusion Pharmaceuticals Inc. | A strategic decision was made to discontinue the study and prioritize other programs within the… | Safety / toxicity |
| NCT04129515 | NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis | Phase 1 / Phase 2 | withdrawn | Oct 16, 2019 | Brown University | Contract Issues | Other (stated, no rule matched) |
| NCT06626256 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable… | Phase 1 | withdrawn | Oct 3, 2024 | City of Hope Medical Center | no resource | Other (stated, no rule matched) |
| NCT04688658 | Duvelisib in Combination With Nivolumab in Patients With Advanced Unresectable Melanoma | Phase 1 / Phase 2 | terminated | Dec 30, 2020 | John Kirkwood | Secura Bio, Inc. discontinued support of the trial. | Other (stated, no rule matched) |
| NCT03595683 | Pembrolizumab and EDP1503 in Advanced Melanoma | Phase 2 | terminated | Jul 23, 2018 | University of Chicago | Drug supply no longer available. | Drug supply |
| NCT05393713 | Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit… | Phase 1 | terminated | May 26, 2022 | Mayo Clinic | low/slow accrual | Enrollment / accrual |
| NCT02706353 | APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma | Phase 1 / Phase 2 | terminated | Mar 11, 2016 | M.D. Anderson Cancer Center | \<75% participant accrual | Enrollment / accrual |
| NCT04725331 | A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in… | Phase 1 / Phase 2 | terminated | Jan 26, 2021 | Transgene | Sponsor decision following completion of Phase I part not driven by safety reason | Safety / toxicity |
| NCT06052852 | Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With… | Phase 1 | terminated | Sep 25, 2023 | Bolt Biotherapeutics, Inc. | Sponsor decision | Sponsor / business decision |
| NCT05169437 | Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors(PAVO) | Phase 2 | terminated | Dec 27, 2021 | Tempus AI | Recruitment challenges | Enrollment / accrual |
| NCT01546571 | Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients(MAVIS) | Phase 3 | terminated | Mar 7, 2012 | Polynoma LLC | After interim analysis the study was halted to redesign a pivotal trial. | Efficacy / futility |
| NCT04543188 | A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and… | Phase 1 | terminated | Sep 10, 2020 | Pfizer | Pfizer has made an internal business decision to not continue further development of PF-07284890.… | Safety / toxicity |
| NCT03901573 | High-Risk Skin Cancers With Atezolizumab Plus NT-I7 | Phase 1 / Phase 2 | terminated | Apr 3, 2019 | NeoImmuneTech | Strategic decision by sponsor | Sponsor / business decision |
| NCT04935229 | Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO),… | Phase 1 | terminated | Jun 22, 2021 | TriSalus Life Sciences, Inc. | The decision was made to terminate the study after the completion of Phase 1 enrollment and not… | Safety / toxicity |
| NCT05229601 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Feb 8, 2022 | HiFiBiO Therapeutics | The decision to discontinue the trial was made as part of a strategic review of the Sponsor's… | Safety / toxicity |
| NCT06275854 | YASU Research Registry: For Young Adults With Cancer | — | terminated | Feb 23, 2024 | Young Adult Survivors United | Sponsoring organization no longer desired to recruit/maintain registry | Enrollment / accrual |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | Phase 2 | terminated | Aug 2, 2021 | Day One Biopharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT03712904 | Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal… | Phase 2 | terminated | Oct 19, 2018 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT06270082 | Study of IK-595 in RAS- or RAF-altered Advanced Tumors | Phase 1 | terminated | Feb 21, 2024 | Ikena Oncology | Limited resources and strategic priorities | Sponsor / business decision |
| NCT02967692 | A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in…(COMBI-i) | Phase 3 | terminated | Nov 18, 2016 | Novartis Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT06285097 | A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced… | Phase 1 | terminated | Feb 29, 2024 | Pfizer | The trial was terminated for strategic business reasons; the decision was not based on any safety… | Safety / toxicity |
| NCT05388877 | E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF… | Phase 1 | terminated | May 24, 2022 | Mayo Clinic | Financial issues | Funding |
| NCT07121829 | Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and… | Phase 1 | terminated | Aug 14, 2025 | Day One Biopharmaceuticals, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04941430 | 7T MRI Scan for the Early Detection of Melanoma Brain Metastases | N/A | terminated | Jun 28, 2021 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT05717140 | Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With… | Phase 1 | withdrawn | Feb 8, 2023 | Mayo Clinic | Lack of funding | Funding |
| NCT03698162 | Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma… | N/A | terminated | Oct 5, 2018 | University of Southern California | Slow accrual | Enrollment / accrual |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Nov 2, 2018 | MacroGenics | Business decision | Sponsor / business decision |
| NCT04904185 | ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to… | Phase 1 | terminated | May 27, 2021 | Inge Marie Svane | Evaluation of step A did not support addition of pembrolizumab in step B | Other (stated, no rule matched) |
| NCT00087776 | Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant… | Phase 3 | terminated | Jul 16, 2004 | American Regent, Inc. | Interim analysis determined that the futility boundary had been crossed and there was no reasonable… | Efficacy / futility |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Mar 7, 2024 | Numab Therapeutics AG | Business decision | Sponsor / business decision |
| NCT04720417 | Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma | Phase 2 | terminated | Jan 22, 2021 | Thomas Jefferson University | Trial enrollment was stopped early by study sponsors (before the anticipated accrual of 18… | Enrollment / accrual |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | Phase 1 | terminated | Oct 4, 2019 | Craig L Slingluff, Jr | Unable to enroll enough patients to complete targeted enrollment in a reasonable time. | Enrollment / accrual |
| NCT06508827 | Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma | Phase 2 | withdrawn | Jul 18, 2024 | Indiana University | Difficulty recruiting participants | Enrollment / accrual |
| NCT03991741 | Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose… | Phase 1 | terminated | Jun 19, 2019 | Gregory Daniels | Closed because of feasibility and safety issues, didn't reach our end point | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Mar 18, 2026source: clinicaltrials